spacer
home > pmps > winter 2018 > patience with patients
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Patience with Patients

What is patient adherence?

As defined by the WHO, patient adherence is the extent to which a person’s behaviour – for example, taking medication, following a diet or executing lifestyle changes – corresponds with the agreed recommendations from a healthcare provider. A low level of adherence means that the likelihood of patients taking their prescribed medication correctly is small, which can be very dangerous, in some cases.

Would you say that this is a growing or lessening concern for the pharmaceutical industry and why?

Patient adherence is currently one of the biggest challenges that the pharma industry is facing and remains a growing concern. Not only do low patient adherence levels affect healthcare efficacy, it is also extremely costly to the industry. Research shows that patients not taking their medication in line with recommendations costs the NHS Ł500 million per year, which, in context, is equivalent to 30,000 kidney transplants or an extra 21,000 qualified nurses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rupert Taylor joined Essentra in 2014 as Global Category Manager Household for food and drink. He is now Global Category Manager for healthcare and personal care. Rupert’s role is to identify customer and consumer needs in the market place and deliver those solutions through the company’s portfolio of packaging, components, special technologies, security, and authentication. Prior to joining Essentra, he worked as Marketing and Innovation Director for Puratos, Brazil. Rupert’s experience spans over 20 years in delivering results in both B2B and B2C environments on a global basis.
spacer
Rupert Taylor
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVT’s commercial activities, including global sales, marketing and customer service.
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 
Industry Events

Biotech Showcase™ 2019

7-9 January 2019, Hilton San Francisco Union Square

Biotech Showcase™ is an investor and networking conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement